GSK struck a headline ADC licensing deal with Syndivia for a preclinical ADC targeting metastatic castration‑resistant prostate cancer, agreeing to pay up to €357 million in upfront and milestone payments and taking on development and commercialization. The ADC uses Syndivia’s GeminiMab platform for site‑specific conjugation to control drug‑to‑antibody ratio and tolerability. SOTIO and other ADC and immunocytokine developers will present new preclinical and translational data at upcoming conferences, signaling renewed industry focus on next‑generation payloads and conjugation platforms to improve the therapeutic window. Early animal data from Syndivia suggest tumor shrinkage without increased toxicity. For oncology developers: the combination of improved conjugation chemistry and novel payloads is driving renewed investor and pharma interest; successful differentiation will require robust translational biomarkers and careful toxicity monitoring in early clinical trials. Commercial note: ADC investments reflect a shift to engineered, site‑specific platforms to manage payload potency and safety—expect increased deal activity and competition for conjugation IP.